Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01737450
Other study ID # ET12-034
Secondary ID 2012-002403-18
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2013
Est. completion date March 2019

Study information

Verified date June 2019
Source Centre Leon Berard
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to determine the activity, to assess the safety and tolerance of BKM120 in adult patients with recurrent or metastatic head and neck cancer progressive under platin and cetuximab-based chemotherapy.


Description:

BKM120 is a PI3K inhibitor. The PI3K/Protein kinase B (AKT) signalling pathway deregulation is frequently observed in Head and neck cancer. In addition to its role in tumor genesis, the PI3K/AKT pathway seems to be involved in resistance to cetuximab.

In this context, the study proposal is to evaluate the clinical interest of a monotherapy with a PI3K inhibitor (BKM120, Novartis) in patients with metastatic head and neck cancers refractory or relapsing under platin and cetuximab based- chemotherapy. Since resistance to cetuximab can result from phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation, PIK3CA amplification or mutation upstream in the PI3K pathway, BKM120 activity will be evaluated in two parallel independent cohorts of patients: patients presenting a PI3KCA mutation and patients without a PI3KCA mutation.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date March 2019
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 1. Adult men and women = 18 years at the day of inform consent signature.

- 2. Patients with metastatic or relapsed squamous cell head and neck carcinoma .

- 3. Documented progression or relapse after platin and cetuximab or anti-epidermal growth factor receptor (EGFR) -based chemotherapy at time of study drug start

- 4. Documented mutational status of PIK3CA before study drug start

- 5. Eastern Cooperative Oncology Group (ECOG) performance status = 2 .

- 6. At least one measurable lesion by CT-scan as per RECIST 1.1 .

- 7. Life expectancy > 12 weeks.

- 8. Patients must be able to swallow capsules.

- 9. Adequate bone marrow, renal and liver function as defined by the following tests :

- Absolute neutrophil count = 1.0 x 109/L,

- Platelet count > 100 x 109/L,

- Haemoglobin value above 9 g/dL,

- international normalized ratio (INR) = 1.5

- Serum Creatinine = 1.5 upper limit of normal (ULN)

- Glomerular filtration rate calculated using Cockcroft-Gault formula > 60ml/min (or MDRD formula for patients older than 65 years)

- Potassium, calcium, magnesium within normal limits for the institution

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < ULN (or < 3.0 x ULN if liver metastases are present))

- Serum bilirubin within normal range (or = 1.5 ULN if liver metastases are present; or total bilirubin = 3.0 ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)

- Fasting plasma glucose (FPG) = 120 mg/dL or = 6.7 mmol/L.

- 10. Women of childbearing potential (entering the study after a confirmed menstrual period and who have a negative pregnancy test within = 72 hours before initiating study treatment) must agree to use two methods of medically acceptable forms of contraception during the whole treatment period and for 1 month (= 5 x t½ of BKM120) after the last treatment intake.

- 11. Fertile males must use a highly effective contraception during dosing of any study agent + [5 x t1/2] + 12 weeks = contraception through 16 weeks after final dose of study therapy and should not father a child in this period. Female partner of male study subject: highly effective contraception during dosing of study agent + 4 weeks after final dose of study therapy

- 12. Patient should be able and willing to comply with study visits and procedures as per protocol.

- 13. Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.

- 14. Patients must be covered by a medical insurance.

Exclusion Criteria:

- 1. Patient having received previous treatment with PI3K and/or mammilian target of rapamycin (mTOR) inhibitors.

- 2. Patient with symptomatic central nervous system (CNS) metastases.

- 3. Patient with a concurrent malignancy or has a malignancy within 3 years of study enrollment, (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer).

- 4. Patient has any of the following mood disorders as judged by the Investigator or a Psychiatrist:

- Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others),

- Patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual (DSM) - IV) are not eligible.

Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug.

- = CTCAE grade 3 anxiety,

- or meets the cut-off score of = 12 in the Patient Health Questionnaire (PHQ) -9 or a cut-off of = 15 in the generalized anxiety disorder (GAD) -7 mood scale, respectively,

- or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9).

- 5. Patient concurrently using other approved or investigational anti-neoplasic agent.

- 6. Patient who has received anticancer therapy < 2 weeks or investigational treatment < 4 weeks prior the initiation of study drug.

- 7. Patient who has received radiotherapy = 4 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia).

- 8. Patient having had major surgery within 14 days prior to starting study drug or has not recovered from major side effects of the surgery.

- 9. Patient with poorly controlled diabetes mellitus (i.e. HbA1c > 8 %)

- 10. Patient with active cardiac disease including any of the following:

- Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO),

- corrected QT interval (QTc) > 480 (female) or 470 msec (male) on screening ECG (using the corrected QT Fridericia (QTcF) formulae),

- Angina pectoris that requires the use of anti-anginal medication,

- Ventricular arrhythmias except for benign premature ventricular contractions,

- Supraventricular and nodal arrythmias requiring a pacemaker or not controlled with medication,

- Conduction abnormality requiring a pacemaker,

- Valvular disease with documented compromise in cardiac function,

- Symptomatic pericarditis.

- 11. Patient with a history of cardiac dysfunction including any of the following:

- Myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF function,

- History of documented congestive heart failure (New York Heart Association functional classification III-IV),

- Documented cardiomyopathy,

- Other cardiac arrhythmia not controlled with medication.

- 12. Patient currently receiving treatment with QT prolonging medication known to have a risk to induce Torsades de Pointes, and if the treatment cannot be discontinued or switched to a different medication prior to starting study drug.

- 13. Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120

- 14. Patient receiving chronic treatment (> 5 days) with steroids or another immunosuppressive agent. Note: Topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular) are allowed. Patients with previously treated brain metastases, who are on a stable low dose corticosteroids treatment (e.g., dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment, are eligible.

- 15. Patient has other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate her participation in the clinical study

- 16. Patient has a history of non-compliance to medical regimen.

- 17. Patient is currently being treated with drugs known to be strong inhibitors or inducers of isoenzyme Cytochrome P450 family 3 subfamily A member 4 (CYP3A), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.

- 18. Patient has a known history of HIV infection.

- 19. Pregnant or nursing (lactating) woman.

- 20. Patient has a known hypersensitivity to any of the excipients of BKM120.

- 21. Patient has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy.

- 22. Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin, or fondaparinux is allowed.

- 23. Patient has acute viral hepatitis or a history of chronic or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, typically defined by elevated AST/ALT (persistent or intermittent), high HBV DNA level, HBsAg positive, or high HCV RNA level (testing not mandatory)

Study Design


Intervention

Drug:
BKM120


Locations

Country Name City State
France Hopital St André Bordeaux
France Hôpital BEAUJON Clichy
France Centre Oscar Lambret Lille
France Centre Léon Bérard Lyon
France Centre Val d'Aurelle - Paul Lamarque Montpellier
France Centre Antoine LACASSAGNE Nice
France Institut Curie Paris
France Centre Hospitalier Lyon Sud Pierre Benite
France Institut Gustave Roussy Villejuif

Sponsors (3)

Lead Sponsor Collaborator
Centre Leon Berard Fondation ARC, National Cancer Institute, France

Country where clinical trial is conducted

France, 

References & Publications (5)

Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review. — View Citation

Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 2008 May 29;453(7195):662-6. doi: 10.1038/nature06892. Epub 2008 Apr 30. — View Citation

Saranath D, Panchal RG, Nair R, Mehta AR, Sanghavi VD, Deo MG. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Eur J Cancer B Oral Oncol. 1992 Oct;28B(2):139-43. — View Citation

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044. — View Citation

Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993 Jan 21;328(3):184-94. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 2 months disease control rate Control rate= Complete response, partial response and stable disease according to RECIST 1.1 2 months after the first BKM120 intake
Secondary Progression free survival At 2 months, 4 months and then every 2 months
Secondary Overall survival (OS) OS will be measured from the date of inclusion to the date of death from any cause. Baseline, at 2 months, 4 months and then every 2 months at the end of Study
Secondary Safety The assessment of safety will be based mainly on the frequency of adverse events based on the common toxicity criteria adverse event (CTCAE) V4.0 grade. continuous up to 30 days after the last treatment
Secondary Objective response rate Objective response rate is defined as the proportion of patient with complete or partial response according RECIST 1.1 At Baseline, 2 months, 4 months and then every 2 months, at the end of Study
Secondary Duration of response The duration of response will be measured from the time of first documented response until the first documented disease progression or death due to underlying cancer. At Baseline, 2 months, 4months and then every 2 months, at the end of Study
Secondary Time to Progression Time to Progression will be measured from the time of treatment start until the first documented disease progression. Patients with no event at the time of the analysis will be censored at their last tumor assessment date. At Baseline, 2 months, 4months and then every 2 months, at the end of Study
See also
  Status Clinical Trial Phase
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT04458259 - Study of PF-07265807 in Participants With Metastatic Solid Tumors. Phase 1
Completed NCT01218542 - Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc N/A
Not yet recruiting NCT03175146 - A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely N/A
Active, not recruiting NCT02395224 - A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT01960829 - Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study Phase 2
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00207116 - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma Phase 1
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4